Browsing Tag
Basel
8 posts
Can Swiss Rockets’ new CoolMPS deal with MGI Tech make Europe a genomics powerhouse?
Find out how Swiss Rockets AG’s exclusive license for MGI Tech’s CoolMPS sequencing platform could redefine genomics and precision medicine worldwide.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
89bio stock soars 85% as Roche seals $3.5bn takeover—What’s behind the surge and what’s next?
Roche is buying 89bio for up to $3.5B to add Phase 3 MASH drug pegozafermin. Find out what the CVR means and how investors should read the deal today.
Novartis to acquire Regulus Therapeutics in $1.7bn deal to advance farabursen for ADPKD treatment
Novartis to acquire Regulus Therapeutics for $1.7 billion, gaining next-gen kidney drug farabursen for ADPKD. Read the market reaction and deal insights.
Roche bets big on America: $50bn to fuel next-gen weight loss drugs and diagnostics boom
Discover how Roche’s $50 billion U.S. investment is transforming pharma R&D, diagnostics, and job creation across eight states and reshaping global exports.
Novartis achieves 22% rise in core operating income, driven by innovative medicines
Novartis has reported a stellar performance for the fourth quarter of 2024, showcasing impressive growth across its core…
Novartis company profile: A global leader redefining healthcare innovation
What is the history of Novartis and its establishment? Novartis emerged in 1996 following the merger of Ciba-Geigy…
Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology,…